- Home
- RNAZ vs GNPX Comparison
RNAZ vs GNPX Comparison
Compare RNAZ & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- GNPX
- Stock Information
- Founded
- RNAZ 2016
- GNPX 2009
- Country
- RNAZ United States
- GNPX United States
- Employees
- RNAZ N/A
- GNPX N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- GNPX Health Care
- Exchange
- RNAZ Nasdaq
- GNPX Nasdaq
- Market Cap
- RNAZ 6.1M
- GNPX 5.5M
- IPO Year
- RNAZ 2021
- GNPX 2018
- Fundamental
- Price
- RNAZ $10.97
- GNPX $0.23
- Analyst Decision
- RNAZ Strong Buy
- GNPX
- Analyst Count
- RNAZ 1
- GNPX 0
- Target Price
- RNAZ $280.00
- GNPX N/A
- AVG Volume (30 Days)
- RNAZ 14.3K
- GNPX 13.6M
- Earning Date
- RNAZ 08-14-2025
- GNPX 08-14-2025
- Dividend Yield
- RNAZ N/A
- GNPX N/A
- EPS Growth
- RNAZ N/A
- GNPX N/A
- EPS
- RNAZ N/A
- GNPX N/A
- Revenue
- RNAZ N/A
- GNPX N/A
- Revenue This Year
- RNAZ N/A
- GNPX N/A
- Revenue Next Year
- RNAZ N/A
- GNPX N/A
- P/E Ratio
- RNAZ N/A
- GNPX N/A
- Revenue Growth
- RNAZ N/A
- GNPX N/A
- 52 Week Low
- RNAZ $6.15
- GNPX $0.14
- 52 Week High
- RNAZ $739.20
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- RNAZ 55.77
- GNPX 58.63
- Support Level
- RNAZ $9.29
- GNPX $0.14
- Resistance Level
- RNAZ $10.48
- GNPX $0.17
- Average True Range (ATR)
- RNAZ 0.66
- GNPX 0.03
- MACD
- RNAZ 0.02
- GNPX 0.01
- Stochastic Oscillator
- RNAZ 100.00
- GNPX 77.49
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.